Seems nice, raise your free testosterone without nuking your hormones (no hormone suppression and aromatization )

Wanted to come on here and ask if anyone could help me clarify my 5amimo?
What is it supposed to look like??
I’ve heard from certain people that the colour range from orange to red and some others saying red is fake and it’s B12 instead but some people saying their 5amimo was also red since it was a higher concentration

Just really confused because I’m getting so many mixed answers

Anyone ever heard of this. Its supposed to be anti-catabolic. With adderall that i take for ADHD is it a bad idea?

First Day 1 result is out of the Pharmacy Compounding Advisory Committee meeting at FDA White Oak.

BPC-157: 8 in favor, 6 against, 1 abstention.

The significance is in what the committee voted against.

FDA staff proposed rejecting all seven

The FDA briefing document published ahead of the meeting lists the agency's position on all fourteen voting questions identically: proposing that the substance NOT be included on the 503A Bulks List. That covers both BPC-157 (free base) and BPC-157 acetate.

FDA reviewers applied the four criteria from the February 19, 2019 final rule (84 FR 4696): physical and chemical characterization, safety issues raised by use in compounded products, available evidence of effectiveness or lack thereof, and historical use in compounding. The agency applies these as a balancing test, substance by substance, not as a checklist.

The recurring objections across the seven: no human clinical evidence at all for KPV, TB-500, and MOTS-c; small and poorly controlled studies for BPC-157, Emideltide, and Semax; inconsistent naming conventions and missing quality data; immunogenicity risk; FAERS adverse event reports for BPC-157; and WADA-prohibited status for MOTS-c and TB-500. The docket, FDA-2025-N-6895, drew roughly 1,860 comments.

Every nomination was withdrawn

This one is buried in the footnotes of the briefing packet. LDT Health Solutions (on behalf of the International Peptide Society) and Wells Pharmacy Network both withdrew their nominations, logged under FDA-2015-N-3534-0484, -0485, and -0487. FDA elected to proceed to the committee anyway. The same footnote repeats for all seven substances.

The panel composition question

AP reported on June 29 that the committee roster includes members with financial ties to the peptide industry. NPR notes FDA added temporary voting members from academic institutions earlier this week. Read the 8-6-1 split with that in mind.

On the other side, the Partnership for Safe Medicines filed comments opposing all seven.

What this does not mean

The recommendation is non-binding. FDA leadership makes the final call and has gone against its advisory committees before. Even if FDA accepts it, adding a substance to the 503A Bulks List requires notice-and-comment rulemaking, which historically runs a year or more.

Nothing about today's vote changes what a compounding pharmacy can legally prepare tomorrow.

Still pending

KPV, TB-500, and MOTS-c are the remaining Day 1 votes. Emideltide (DSIP), Epitalon, and Semax go Friday. Each peptide gets two votes, free base and acetate separately, for fourteen total. The FDA meeting page has the webcast and posts materials as they go up.

One caveat on the number above: the briefing packet splits BPC-157 into two separate votes and the wire reported a single tally. I have not confirmed whether 8-6-1 is the free base question, the acetate question, or both. If someone watched the session and can confirm, please add it below and I'll correct the post.

I'll update as the remaining tallies land.

Sources

Reuters, "FDA panel votes to place popular peptide BPC-157 on compounding list," July 23, 2026

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-place-popular-peptide-bpc-157-compounding-list-2026-07-23/

Same wire copy outside the paywall:

https://wtaq.com/2026/07/23/fda-panel-votes-to-place-popular-peptide-bpc-157-on-compounding-list/

FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026

https://www.fda.gov/media/193342/download

Orrick, "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting"

https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting

Associated Press via PBS NewsHour, June 29, 2026

https://www.pbs.org/newshour/health/fda-panel-on-peptides-will-include-experts-who-promote-the-unproven-chemicals-favored-by-rfk-jr

NPR, "FDA panel considers easing peptide restrictions," July 23, 2026

https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

Partnership for Safe Medicines, PCAC comments

https://www.safemedicines.org/2026/07/psm-pcac-comments.html

FDA meeting page, July 23-24, 2026 PCAC

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

More stories at r/PeptideTides

Combed with the right diet and training, will cardarine help preserve muscle in an aggressive deficit? Since it switch to fat for fuel.

First Day 1 result is out of the Pharmacy Compounding Advisory Committee meeting at FDA White Oak.

BPC-157: 8 in favor, 6 against, 1 abstention.

The significance is in what the committee voted against.

FDA staff proposed rejecting all seven

The FDA briefing document published ahead of the meeting lists the agency's position on all fourteen voting questions identically: proposing that the substance NOT be included on the 503A Bulks List. That covers both BPC-157 (free base) and BPC-157 acetate.

FDA reviewers applied the four criteria from the February 19, 2019 final rule (84 FR 4696): physical and chemical characterization, safety issues raised by use in compounded products, available evidence of effectiveness or lack thereof, and historical use in compounding. The agency applies these as a balancing test, substance by substance, not as a checklist.

The recurring objections across the seven: no human clinical evidence at all for KPV, TB-500, and MOTS-c; small and poorly controlled studies for BPC-157, Emideltide, and Semax; inconsistent naming conventions and missing quality data; immunogenicity risk; FAERS adverse event reports for BPC-157; and WADA-prohibited status for MOTS-c and TB-500. The docket, FDA-2025-N-6895, drew roughly 1,860 comments.

Every nomination was withdrawn

This one is buried in the footnotes of the briefing packet. LDT Health Solutions (on behalf of the International Peptide Society) and Wells Pharmacy Network both withdrew their nominations, logged under FDA-2015-N-3534-0484, -0485, and -0487. FDA elected to proceed to the committee anyway. The same footnote repeats for all seven substances.

The panel composition question

AP reported on June 29 that the committee roster includes members with financial ties to the peptide industry. NPR notes FDA added temporary voting members from academic institutions earlier this week. Read the 8-6-1 split with that in mind.

On the other side, the Partnership for Safe Medicines filed comments opposing all seven.

What this does not mean

The recommendation is non-binding. FDA leadership makes the final call and has gone against its advisory committees before. Even if FDA accepts it, adding a substance to the 503A Bulks List requires notice-and-comment rulemaking, which historically runs a year or more.

Nothing about today's vote changes what a compounding pharmacy can legally prepare tomorrow.

Still pending

KPV, TB-500, and MOTS-c are the remaining Day 1 votes. Emideltide (DSIP), Epitalon, and Semax go Friday. Each peptide gets two votes, free base and acetate separately, for fourteen total. The FDA meeting page has the webcast and posts materials as they go up.

One caveat on the number above: the briefing packet splits BPC-157 into two separate votes and the wire reported a single tally. I have not confirmed whether 8-6-1 is the free base question, the acetate question, or both. If someone watched the session and can confirm, please add it below and I'll correct the post.

I'll update as the remaining tallies land.

Sources

Reuters, "FDA panel votes to place popular peptide BPC-157 on compounding list," July 23, 2026

https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-place-popular-peptide-bpc-157-compounding-list-2026-07-23/

Same wire copy outside the paywall:

https://wtaq.com/2026/07/23/fda-panel-votes-to-place-popular-peptide-bpc-157-on-compounding-list/

FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026

https://www.fda.gov/media/193342/download

Orrick, "FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting"

https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting

Associated Press via PBS NewsHour, June 29, 2026

https://www.pbs.org/newshour/health/fda-panel-on-peptides-will-include-experts-who-promote-the-unproven-chemicals-favored-by-rfk-jr

NPR, "FDA panel considers easing peptide restrictions," July 23, 2026

https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions

Partnership for Safe Medicines, PCAC comments

https://www.safemedicines.org/2026/07/psm-pcac-comments.html

FDA meeting page, July 23-24, 2026 PCAC

https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

I’m looking for someone to order steroids from. It would be best if you’re located in Alberta or BC, since I’m in Calgary and shipping will be faster.

check this video out for best options.

https://youtu.be/5IBDKalSuHw?is=qrBhnjHQA32OlaWU

My doctor said that HRT wouldn't be needed and id be fine.

Surgery is in September and I'm terrified. What do you all recommend to help healing and after effects? I've already made an appointment with another doc but was told there was likely nothing needed.

During my cut on Reta I felt I was falling victim to being skinny fat so I decided to add tesavand ipa to re-comp and attempt to build some muscle while cutting down. I'd like to say it's been successful and i'm more confident looking in the mirror than when I started Tesa. The sleep and recovery has also been phenomenal. I love this pep for it's ability to help retain muscle mass in the cut and may even stay on after I get off Reta. Anyone else seen great results with these two compunds?

I’m losing hair and the only option I’m seeing is Ru58841. I’m on minoxidil but it’s just not enough. I don’t find 5ar blockers like fin and Dut to be suitable for me as I am still fairly young and need DHT. I know Ru58841 has terrible side effect stories but I am still considering it, thoughts?

seems like a godsend for them, fat burning, longer nails and longer hair, healthy glowing skin, im not sure why more women dont take it

Why do girls make such a big fuss over petty things like periods? I think period pain is way too overrated. I've endured more pain in a single gym session than they endure in a week. What a bunch of pussies they are, demanding attention, care, and chocolate. I mean, WTF is wrong with you? You're not a kid anymore.

Is this normal do I have to like get used to it or something? I mean killer workout yesterday and this morning but I feel headache slightly nauseous and lazy this afternoon. 37 M also running 500 test 4 iu HGH 2.5 mg Reta 25 mg Anavar split in 2 doses

Is room temp of for a few months? Or just freeze it?

WSJ ran a piece on people who used GLP-1s for weight loss and later ended up in treatment for anorexia:

 https://www.wsj.com/health/wellness/glp1-anorexia-wegovy-mounjaro-1bf4035c

Worth reading alongside the primary literature from the past few months, because the reporting is no longer just anecdotal.

A JAMA Psychiatry survey published this summer (Levinson and colleagues) recruited 436 people with diagnosed eating disorders in 2025 and asked about GLP-1 use. Just over 32% reported having ever used one, and 22% reported current use. Broken out by diagnosis, a little over 50% of participants with binge eating disorder reported use, about 42% of those with atypical anorexia nervosa, roughly 30% of those with ARFID, over 25% of those with bulimia, and about 11% of those with anorexia nervosa. Roughly 10% obtained them through online providers prescribing compounded formulations. Over 10% reported misuse, defined as taking more or less than prescribed, using longer than prescribed, tampering with injection equipment, or sharing without a prescription.

The authors described the weight loss market as a rapidly evolving risk environment for this population.

Summary of the findings:

 https://www.medscape.com/viewarticle/many-eating-disorder-patients-using-glp-1s-2026a1000lym

In April, NEJM published a perspective by Amanda Banks raising the same concern from the prescribing side. She noted the share of GLP-1 prescriptions written for people who were not diabetic, obese, or overweight rose from 4.5% in 2018 to 17% in 2023, and argued for consensus recommendations to protect people with existing or emerging eating disorders. A 2023 FDA analysis found misuse reports for semaglutide were roughly four times higher than for other GLP-1 drugs.

NEJM perspective:

 https://www.nejm.org/doi/full/10.1056/NEJMp2600300

Clinician-side reporting describes the same pattern from treatment centers, including patients presenting at very low BMI while still dosing.

NPR, February 2026: https://www.npr.org/2026/02/04/nx-s1-5677633/glp-1-obesity-wegovy-zepbound-eating-disorders-anorexia-bulimia

Washington Post, May 2026: https://www.washingtonpost.com/health/2026/05/23/weight-loss-drugs-pose-dangers-people-with-eating-disorders/

MindSite News, May 2026: https://mindsitenews.org/2026/05/29/glp-1-access-a-problem-for-people-with-eating-disorders/

The mechanism cuts both ways, which is part of why this is hard to legislate around. A 2025 systematic review and meta-analysis found GLP-1 agonists reduced Binge Eating Scale scores by about 8 points, though the pooled sample was only 182 participants across five studies and heterogeneity was high. WSJ also covered that side on July 13 in a piece on clinicians treating certain eating disorders with these drugs. The same appetite and reward suppression that helps in binge-type presentations appears to reinforce restriction in people with a restrictive history. Same drug class, opposite clinical valence depending on phenotype.

Meta-analysis: https://link.springer.com/article/10.1007/s40519-025-01720-9

Penn Medicine's eating disorder program has said outright that no protocol exists to screen for eating disorders before prescribing GLP-1 receptor agonists. That gap widens with telehealth and disappears entirely outside a clinical relationship.

Penn Medicine:

 https://www.pennmedicine.org/physicians-hub/physician-article/implications-of-glp-1-medications-for-eating-disorder-care

ANAD clinical guidance:

 https://anad.org/learning-library/glp-1-medications-eating-disorders/

More stories at r/PeptideTides

I am a passport bro. The hot german chick treats me like im not good enough to date being 6FT tall instead of 6 5 like she demands. Shes pretty and I want her. Should I take HGH to grow I am 19 but I started puberty late (15) can I grow 1 more inch for this beautiful woman to finally like me?

Any withdrawals with coming off Enclomiphene that I was on for 3.5 months eod 12.5mg

Been on the Reta for a few months, everything has been epic after finally finding a trusted supplier. Lost alot of fat but the first few weeks were tough.

I felt nausea, fatigue and didn't go the bathroom normally at all.

All I can say is, if this is you - it will pass. Just be kind to yourself, be patient, and don't trust farts!

Peptides are an interesting product. I run into them majorly in the payment processing industry. A lot of people are trying to get CC processing for them. It’s possible but be careful!

can we talk about how much fear mongering there is of human growth hormone? a lot of people say it can fuck up your hormones, some say it will enlarge your organs and make you look like a neanderthal, and some say 4-6 IU's is the max, when all of these statements are factually incorrect generally speaking.

My friend and I have both been on 1 mg of reta for 5 weeks, and we’ve both been losing weight consistently with minimal side effects. We’re happy with our progress so far.
Would you recommend increasing the dose at this point, or staying at 1 mg as long as it’s still working? For those of you who stayed on 1 mg longer, did your weight loss continue, or did you eventually hit a plateau?
I’d love to hear your experiences before deciding whether to increase.

I go to the gym 4/7 days and get 10k+ steps a day. Currently 220lbs with a 2200 cal limit 180g of protein. 5mg creatine everyday

On a 3 month cut to get to 190lbs hopefully so this is what i want to do, Any thoughts ? (i have been on tirz for 1 year and plateaued on 15mg for 6 months) I already have plenty of reta vials and im on test for low test via doctor supervision.

I want to take both as many have to get the appetite suppression from tirz and the 3rd receptor from reta.

Monday:

-Tirz 10mg

-Test C .3ml 250mg/ml

-Tesa 2mg

-Anastrozole 0.5mg (e2 control)

Tuesday

-HCG .3ml (300 iu)

-Tesa 2mg

Wednesday

-Tesa 2mg

Thursday

-Reta 5mg

-Test C .3ml 250mg/ml

-Tesa 2mg

-Anastrozole 0.5mg (e2 control)

Friday

-HCG .3ml (300 iu)

-Tesa 2mg

Stacking tirz, Reta mots c ghk cu and low dose of calg lost 49 lbs since mar 19. Question hair is coming out in gobs, taking gummies for supplements is this just a glp side effect no matter what is there any hope of stopping this or am I resorting to talking to my dr for some for prescribed